Literature DB >> 26908865

Field Synopsis of Sex in Clinical Prediction Models for Cardiovascular Disease.

Jessica K Paulus1, Benjamin S Wessler2, Christine Lundquist2, Lana L Y Lai2, Gowri Raman2, Jennifer S Lutz2, David M Kent2.   

Abstract

BACKGROUND: Several widely used risk scores for cardiovascular disease (CVD) incorporate sex effects, yet there has been no systematic summary of the role of sex in clinical prediction models (CPMs). To better understand the potential of these models to support sex-specific care, we conducted a field synopsis of sex effects in CPMs for CVD. METHODS AND
RESULTS: We identified CPMs in the Tufts Predictive Analytics and Comparative Effectiveness CPM Registry, a comprehensive database of CVD CPMs published from January 1990 to May 2012. We report the proportion of models including sex effects on CVD incidence or prognosis, summarize the directionality of the predictive effects of sex, and explore factors influencing the inclusion of sex. Of 592 CVD-related CPMs, 193 (33%) included sex as a predictor or presented sex-stratified models. Sex effects were included in 78% (53/68) of models predicting incidence of CVD in a general population, versus only 35% (59/171), 21% (12/58), and 17% (12/72) of models predicting outcomes in patients with coronary artery disease, stroke, and heart failure, respectively. Among sex-including CPMs, women with heart failure were at lower mortality risk in 8 of 8 models; women undergoing revascularization for coronary artery disease were at higher mortality risk in 10 of 12 models. Factors associated with the inclusion of sex effects included the number of outcome events and using cohorts at-risk for CVD (rather than with established CVD).
CONCLUSIONS: Although CPMs hold promise for supporting sex-specific decision making in CVD clinical care, sex effects are included in only one third of published CPMs.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  cardiovascular diseases; prevention and control; prognosis; risk factors; sex; sex characteristics; women

Mesh:

Year:  2016        PMID: 26908865      PMCID: PMC5573163          DOI: 10.1161/CIRCOUTCOMES.115.002473

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  45 in total

Review 1.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.

Authors:  Lori Mosca; Carole L Banka; Emelia J Benjamin; Kathy Berra; Cheryl Bushnell; Rowena J Dolor; Theodore G Ganiats; Antoinette S Gomes; Heather L Gornik; Clarissa Gracia; Martha Gulati; Constance K Haan; Debra R Judelson; Nora Keenan; Ellie Kelepouris; Erin D Michos; L Kristin Newby; Suzanne Oparil; Pamela Ouyang; Mehmet C Oz; Diana Petitti; Vivian W Pinn; Rita F Redberg; Rosalyn Scott; Katherine Sherif; Sidney C Smith; George Sopko; Robin H Steinhorn; Neil J Stone; Kathryn A Taubert; Barbara A Todd; Elaine Urbina; Nanette K Wenger
Journal:  Circulation       Date:  2007-02-19       Impact factor: 29.690

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Authors:  Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

4.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Authors:  David M Kent; Rodney A Hayward
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

5.  Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines.

Authors:  Muhammad Rizwan Sardar; Marwan Badri; Catherine T Prince; Jonathan Seltzer; Peter R Kowey
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

6.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.

Authors:  Stuart J Pocock; Cono A Ariti; John J V McMurray; Aldo Maggioni; Lars Køber; Iain B Squire; Karl Swedberg; Joanna Dobson; Katrina K Poppe; Gillian A Whalley; Rob N Doughty
Journal:  Eur Heart J       Date:  2012-10-24       Impact factor: 29.983

7.  Don't assume women are the same as men: include them in the trial.

Authors:  Rita F Redberg
Journal:  Arch Intern Med       Date:  2012-06-25

Review 8.  Representation of women in randomized clinical trials of cardiovascular disease prevention.

Authors:  Chiara Melloni; Jeffrey S Berger; Tracy Y Wang; Funda Gunes; Amanda Stebbins; Karen S Pieper; Rowena J Dolor; Pamela S Douglas; Daniel B Mark; L Kristin Newby
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-02-16

9.  Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator.

Authors:  Robert W Rho; Kristen K Patton; Jeanne E Poole; John G Cleland; Ramin Shadman; Inder Anand; Aldo Pietro Maggioni; Peter E Carson; Karl Swedberg; Wayne C Levy
Journal:  Circulation       Date:  2012-10-16       Impact factor: 29.690

10.  Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.

Authors:  Yoshinobu Onuma; Neville Kukreja; Joost Daemen; Hector M Garcia-Garcia; Nieves Gonzalo; Jin Ming Cheng; Piet Hein van Twisk; Ron van Domburg; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2009-07       Impact factor: 11.195

View more
  7 in total

1.  Racial and Ethnic Differences in Graft Loss Among Female Liver Transplant Recipients.

Authors:  S Dave; J L Dodge; N A Terrault; M Sarkar
Journal:  Transplant Proc       Date:  2018-06       Impact factor: 1.066

2.  Annual Women's Issue.

Authors:  Harlan M Krumholz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-02

Review 3.  Cardiovascular Disease Risk Modeling for Astronauts: Making the Leap From Earth to Space.

Authors:  Janice L Huff; Ianik Plante; Steve R Blattnig; Ryan B Norman; Mark P Little; Amit Khera; Lisa C Simonsen; Zarana S Patel
Journal:  Front Cardiovasc Med       Date:  2022-05-19

4.  Acetaminophen-induced Acute Liver Failure Is More Common and More Severe in Women.

Authors:  Jessica B Rubin; Bilal Hameed; Michelle Gottfried; William M Lee; Monika Sarkar
Journal:  Clin Gastroenterol Hepatol       Date:  2017-12-02       Impact factor: 11.382

Review 5.  Tufts PACE Clinical Predictive Model Registry: update 1990 through 2015.

Authors:  Benjamin S Wessler; Jessica Paulus; Christine M Lundquist; Muhammad Ajlan; Zuhair Natto; William A Janes; Nitin Jethmalani; Gowri Raman; Jennifer S Lutz; David M Kent
Journal:  Diagn Progn Res       Date:  2017-12-21

6.  Investigation of Gender Differences and Exclusive Criteria in a Diabetic Acute Ischemic Stroke Population Treated with Recombinant Tissue-Type Plasminogen Activator (rtPA).

Authors:  Taylor Wapshott; Brice Blum; Williams Kelsey; Thomas I Nathaniel
Journal:  J Vasc Interv Neurol       Date:  2017-12

7.  Associations of the MCM6-rs3754686 proxy for milk intake in Mediterranean and American populations with cardiovascular biomarkers, disease and mortality: Mendelian randomization.

Authors:  Caren E Smith; Oscar Coltell; Jose V Sorlí; Ramón Estruch; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Montserrat Fitó; Fernando Arós; Hassan S Dashti; Chao Q Lai; Leticia Miró; Lluís Serra-Majem; Enrique Gómez-Gracia; Miquel Fiol; Emilio Ros; Stella Aslibekyan; Bertha Hidalgo; Marian L Neuhouser; Chongzhi Di; Katherine L Tucker; Donna K Arnett; José M Ordovás; Dolores Corella
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.